CIPDD researchers have extensive experience in establishing, refining and characterising rodent pain models using a range of in vivo methods (behaviour and imaging, the latter in collaboration with scientists at the UQ Centre for Advanced Imaging), and ex vivo techniques including histology, immunohistochemistry, ELISA/multiplexed ELISA, and molecular biology (Western Blot, qPCR).  These skills are applied to the following specific research programs:

  • Investigation of the pathobiology of individual pain conditions

 

  • Analgesic efficacy and adverse event profiling, and mode of action assessment of novel compounds with potential to be progressed into development as new analgesics for human use

Pain (Neuropathic and Chronic Inflammatory): Rodent Models

  • Antiretroviral drug induced peripheral neuropathy (x 2)
  • Cancer chemotherapy induced peripheral neuropathy (CIPN)
  • Painful diabetic neuropathy (x 2)
  • Chronic constriction injury (CCI) of the sciatic nerve
  • MS-associated central neuropathic pain
  • Prostate cancer induced bone pain
  • Breast cancer induced bone pain
  • Capsaicin-induced hindpaw hypersensitivity
  • Monoiodoacetate-induced osteoarthritis
  • FCA-induced inflammatory pain
  • Mechanical low back pain
  • Post-surgical pain (Brennan model)
  • Acute nociceptive pain (x 3)

Collaborative Research on Opioid pharmacology

  • In vivo profiling of novel opioid ligands
  • Identify new molecules from collaborators that evoke:
    • potent analgesia
    • minimal respiratory depression and/or constipation

Sustained Release Drug Delivery of Analgesics for Cancer-related Pain

  • Collaborative research with Professor Andrew Whittaker and colleagues (UQ AIBN)
  • Bioanalytical method development and validation for quantification of molecules of interest to our collaborations with clinicians
    • This aspect of our Centre’s research is led by Dr Sussan Ghassabian (Research Fellow, CIPDD)

Current research projects include collaborations with Professor John Fraser and Associate Professor Kiran Shekar (The Prince Charles Hospital) on the impact of extracorporeal membrane oxygenation (ECMO) and other devices used in critical care on the metabolism and pharmacokinetics of important drugs used clinically.

 

  • Collaboration with Industry

Apart from collaborative research with Industry on a range of competitive grant-funded research projects, CIPDD personnel also conduct contract R&D studies in collaboration with industry on pain-related topics.

 

Collaboration with the TetraQ RIC at The University of Queensland

CIPDD’s GLP recognition by the National Association of Testing Authorities (NATA) means that date from our in vivo toxicology studies undertaken in support of the TetraQ RIC will be accepted for review when included in submissions to international regulatory agencies.